VacZine Analyticsが発行した調査報告書(MR-VAMV061)
◆英語タイトル:MarketVIEW: Ebola virus vaccines - Global vaccine commercial opportunity assessment
◆発行会社(リサーチ会社):VacZine Analytics
◆レポート形式:英語 / PDF or Excel
Executive Presentation (PDF)GBP3,000 ⇒換算¥426,000見積依頼/購入/質問フォーム
Forecast Model (Excel)GBP3,000 ⇒換算¥426,000見積依頼/購入/質問フォーム
PDF+ExcelGBP6,000 ⇒換算¥852,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。VacZine Analytics社の概要及び新刊レポートはこちらでご確認いただけます。


Ebola virus is a member of the Filoviridae family, which can cause a zoonotic disease in humans. The virus can be transmitted between humans via contact with infected body fluids or large droplets of infected fluids, causing a sudden disease with flu-like symptoms, digestive disorders and hemorrhaging. The mean case fatality of historical outbreaks is around 65%. Most Ebola outbreaks occur in central Africa, although latest outbreak is focused on West Africa with around 25,000 cases and over 10,000 deaths (March 2015). It is estimated that the West African region will lose between $3.6 and $4.9 billion in GDP per year for the next 3 years (UNDP figures).

A number of manufacturers are investigating Ebola vaccines in clinical studies. Major companies involved include Okairos/NIAID (GSK), Newlink/PHAC/Merck & Co, Johnson & Johnson. The most advanced in cAd3-EBOZ in Phase II/III Okairos/NIAID (GSK). A number of small molecules, gene silencing technologies and monoclonal antibodies are also being investigated.

This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Ebola vaccines across relevant African countries until 2030. The model contains value ($ m) and volume (mio doses) predictions per vaccine type /per LO/BASE/HIGH scenarios along with timeframe, pricing and penetration estimates for all target populations/stockpile maintenance. The product also includes an in depth review of latest Ebola epidemiological trends, treatments/guidelines and latest developments in R&D.



※レポート紹介PDF⇒ http://www.vaczine-analytics.com/VAMV061_TOC_150401.pdf

****This product is composed of two forecast models and a summary presentation
Author’s note
Executive Summary
Commercial model: key model outputs
Ebola vaccines: global forecast revenue per scenario ($m) to 2030
Ebola vaccines: global forecast revenue ($m), excluding high scenario to 2030
Ebola vaccines: global forecast volume per scenario (m) to 2030
Ebola vaccines: global forecast volume (m), excluding high scenario to 2030
Ebola vaccines: low scenario volume and value to 2030
Ebola vaccines: base scenario volume and value to 2030
Ebola vaccines: high scenario volume and value to 2030
Ebola vaccines: volume by vaccine type to 2030
Ebola vaccines: volume by country – low and base scenarios to 2030
Ebola vaccines: Infant immunisation volume by country (high scenario) to 2030
Ebola vaccines: adult catch-up programme volume by country (high scenario) to 2030
Ebola: disease background and epidemiology
Ebola: the pathogen
Ebola transmission to humans
Ebola transmission between humans
Pathogenesis of Ebola
Clinical presentation of Ebola
Common symptoms, signs and laboratory abnormalities associated with Ebola disease
Mortality and morbidity from Ebola (excluding 2014/15 outbreak)
Diagnosis of Ebola
Diagnosis of Ebola: WHO virus case classification categories
Management of Ebola: treatment and infection control
Ebola: prevalence and incidence worldwide
Ebola: at-risk groups
Focus on 2014/15 West African outbreak: background and disease dynamics
Origins and spread of the 2014/15 outbreak
Factors contributing to the rapid spread and impeded containment of the outbreak
Cumulative cases and deaths over time
Weekly cases: total
Weekly cases: by country
Geographical location of new and total confirmed cases
Spread over time: deaths
Status of the 2014/15 outbreak: March 2015
Nigeria, Senegal, Mali: successful containment avoids extensive outbreaks
Lessons to be learnt for the future
Economic and socioeconomic impact of 2014/15 outbreak
Management of Ebola: treatment and infection control
Personal protective measures for healthcare workers
Supportive management of Ebola cases
Infection control
Therapeutics against Ebola: experimental drugs
Development of therapeutics against Ebola
Small molecules in development for Ebola disease
Gene silencing technologies
ZMapp (Mapp Biopharmaceutical and LeafBio)
Ebola vaccines in development: overview of current R&D
History of Ebola vaccine development
Prospects for the future development of Ebola vaccines
Chimpanzee adenovirus 3-vectored vaccine (cAd3-EBOZ; GSK)
cAd3-EBOZ – phase I and phase II/III studies
VSV G-ZEBOV (rVSV-ZEBOV; Public Health Agency of Canada, NewLink, Merck & Co)
Other Ebola vaccines in development: Ad26.ZEBOV/MVA-BN-Filo (Johnson & Johnson)
PREVAIL: phase II/III study in Liberia with cAd3-EBOZ and rVSV-ZEBOV
Other Phase II/III studies ongoing in West Africa
Vaccination strategies aimed at the current epidemic
Ebola vaccines: immunisation strategies
Factors influencing vaccination strategy decisions
Vaccination strategies for prevention and control of future disease options
Considerations regarding vaccine coverage and efficacy
Ebola vaccine: ideal target product profiles (TPPs)
Ebola vaccines: modelling the current market
Scenarios to be modelled
Countries to be modelled
Vaccine assumptions
Modelling methodology: low scenario
Modelling methodology: base scenario
Modelling methodology: high scenario
About VacZine Analytics

*** PAGES: ~82 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

[Contents – Vaccine demand model TX vaccine (MS Excel-based)]
Title sheet
CHARTS – summary
CHARTS – Lo/base/high
CHARTS – volume per vaccine type
CHARTS – volume per country
Summary volume and value.
Low scenario.
Base scenario.
Hi scenario
High risk infants =>
Liberia’s 26th of May 20
Sierra Leone
South Sudan
Medium risk infants =>
Benin + Burkina Faso
Cameroon + Ghana
Guinea-Bis + Mali
Mauritania + Nigeria
Senegal + Gambia
Togo + Burundi
CAR + Cote D’Ivoire
Kenya + Sudan
Ethiopia + Rwanda
Tanzania + Zambia
Angol + Eq Guinea
Adult Catch-ups =>
Guinea + Liberia
Sierra Leone + Gabon
DRC + Congo
South Sudan + Uganda
Senegal + Guinea-Bissau
Mali + Cote D’Ivoire
Cameroon + CAR
Eq Guinea + The Gambia
Mauritania + Burkina Faso
Ghana + Kenya
Zambia + Angola
Togo + Benin
Nigeria + Sudan
Ethiopia + Rwanda
Burundi + Tanzania
Source data
Birth cohorts
High birth cohort
Infant mortality
Adults 15 yrs
YFV coverage (WHO)
Back page

*** Worksheets ~ 55 interconnected




VacZine Analytics has closely monitored all significant source material pertaining to Ebola virus, current and past outbreaks. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel vaccines has also been utilised.


★リサーチレポート[ エボラウイルスワクチンの世界市場機会分析(MarketVIEW: Ebola virus vaccines - Global vaccine commercial opportunity assessment)]についてメールでお問い合わせはこちらでお願いします。